Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD Inc. has demonstrated a solid positive outlook, highlighted by a 14% year-over-year growth in its Telehealth active subscriber base, reaching 310,818 at the end of the third quarter of 2025, which underscores the increasing demand for its telehealth services. The Telehealth segment generated $47.3 million in revenue, reflecting a significant 17.4% year-over-year increase and contributing to a total revenue of $60.2 million, showcasing an overall growth rate of 12.7% despite a slight miss from projections. Additionally, the company's recent initiatives, such as the introduction of Novo's GLP-1s at competitive pricing, along with the resurgence of the RexMD business and a focus on expanding product offerings, indicate a well-positioned strategy for sustained growth in the telehealth market.

Bears say

LifeMD Inc. reported a revenue of $60.2 million for the quarter, reflecting a 13% year-over-year increase, yet this figure fell short of various expectations, including a consensus estimate of $62.6 million. The company demonstrated a decline in its WorkSimpli segment, with revenue of $12.9 million, representing a 1.7% year-over-year decrease, which, alongside lowered full-year revenue guidance for 2025 to $192-$193 million, indicates possible ongoing struggles in the telehealth market. Additionally, challenges such as pressure from lower-cost competitor offerings, difficulty in acquiring and retaining patients, and a lack of profitability raise significant concerns about LifeMD's future growth potential and overall financial stability.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.